Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 3]
A Phase 3 clinical trial update describes a study evaluating whether odronextamab combined with lenalidomide is safe and more effective than…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial evaluating VR-CAP as first-line therapy for Marginal Zone Lymphoma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T [Phase 1]
This clinical trial update reports long-term follow-up results from a Phase 1 study of CLBR001 CAR-T cells in relapsed/refractory B-cell lym…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study update for VAY736 in non-Hodgkin lymphoma shows the trial status as terminated, evaluating VAY736 alone and in combination wit…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML [Phase 1]
Phase 1 trial update for voruciclib alone or with venetoclax in various B-cell malignancies and acute myeloid leukemia; the study has been t…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating glofitamab and obinutuzumab in indolent non-Hodgkin lymphomas, including follicular lymphoma and marginal …
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results hav…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial evaluating initial therapy with Umbralisib plus Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma was terminated,…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY [Phase 2]
Phase II multicenter open-label single-arm study of pembrolizumab in marginal zone lymphoma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) [Phase 2]
A Phase 2 clinical trial evaluating orelabrutinib in combination with BR/G as first-line therapy for untreated marginal zone lymphoma is cur…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab [Phase 1, Phase 2]
BeiGene announced completion and posted results for a Phase 1/2 study of BGB-10188 as monotherapy and in combination with zanubrutinib and t…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma [Phase 1]
An early-phase study evaluating the combination of parsaclisib with standard therapy in newly diagnosed, high-risk diffuse large B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment [Phase 2]
This update summarizes a Phase 2 trial of zanubrutinib (BGB-3111) in participants with previously treated B-cell lymphomas intolerant to pri…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocy…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractor…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma [Phase 4]
Phase 4 trial evaluating Orelabrutinib with or without a CD20 monoclonal antibody in previously untreated marginal zone lymphoma is currentl…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial is evaluating mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular lymphoma and marginal zone l…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial of Axicabtagene Ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (follicular and marginal zone lymphom…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…